These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
129 related articles for article (PubMed ID: 9396065)
1. Comparative antipsychotic profiles of neurotensin and a related systemically active peptide agonist. Sarhan S; Hitchcock JM; Grauffel CA; Wettstein JG Peptides; 1997; 18(8):1223-7. PubMed ID: 9396065 [TBL] [Abstract][Full Text] [Related]
2. The reversal of amphetamine-induced locomotor activation by a selective neurotensin-1 receptor agonist does not exhibit tolerance. Feifel D; Melendez G; Murray RJ; Tina Tran DN; Rullan MA; Shilling PD Psychopharmacology (Berl); 2008 Oct; 200(2):197-203. PubMed ID: 18568338 [TBL] [Abstract][Full Text] [Related]
3. Synthesis and biological effects of c(Lys-Lys-Pro-Tyr-Ile-Leu-Lys-Lys-Pro-Tyr-Ile-Leu) (JMV2012), a new analogue of neurotensin that crosses the blood-brain barrier. Bredeloux P; Cavelier F; Dubuc I; Vivet B; Costentin J; Martinez J J Med Chem; 2008 Mar; 51(6):1610-6. PubMed ID: 18321036 [TBL] [Abstract][Full Text] [Related]
4. Agonist properties of a stable hexapeptide analog of neurotensin, N alpha MeArg-Lys-Pro-Trp-tLeu-Leu (NT1). Akunne HC; Demattos SB; Whetzel SZ; Wustrow DJ; Davis DM; Wise LD; Cody WL; Pugsley TA; Heffner TG Biochem Pharmacol; 1995 Apr; 49(8):1147-54. PubMed ID: 7748196 [TBL] [Abstract][Full Text] [Related]
5. Involvement of the neurotensin receptor 1 in the behavioral effects of two neurotensin agonists, NT-2 and NT69L: lack of hypothermic, antinociceptive and antipsychotic actions in receptor knockout mice. Mechanic JA; Sutton JE; Berson AE; Wu X; Kwan J; Schreiber R; Pang Z; Button DC Eur Neuropsychopharmacol; 2009 Jul; 19(7):466-75. PubMed ID: 19223157 [TBL] [Abstract][Full Text] [Related]
6. Induction of tolerance to the suppressant effect of the neurotensin analogue NT69L on amphetamine-induced hyperactivity. Hertel P; Byskov L; Didriksen M; Arnt J Eur J Pharmacol; 2001 Jun; 422(1-3):77-81. PubMed ID: 11430916 [TBL] [Abstract][Full Text] [Related]
7. The acute and subchronic effects of a brain-penetrating, neurotensin-1 receptor agonist on feeding, body weight and temperature. Feifel D; Goldenberg J; Melendez G; Shilling PD Neuropharmacology; 2010 Jan; 58(1):195-8. PubMed ID: 19596358 [TBL] [Abstract][Full Text] [Related]
8. The neurotensin-1 receptor agonist PD149163 inhibits conditioned avoidance responding without producing catalepsy in rats. Holly EN; Ebrecht B; Prus AJ Eur Neuropsychopharmacol; 2011 Jul; 21(7):526-31. PubMed ID: 21277173 [TBL] [Abstract][Full Text] [Related]
9. Effects of chronic infusion of neurotensin and a neurotensin NT1 selective analogue PD149163 on amphetamine-induced hyperlocomotion. Norman C; Beckett SR; Spicer CH; Ashton D; Langlois X; Bennett GW J Psychopharmacol; 2008 May; 22(3):300-7. PubMed ID: 18208905 [TBL] [Abstract][Full Text] [Related]
10. Virally mediated increased neurotensin 1 receptor in the nucleus accumbens decreases behavioral effects of mesolimbic system activation. Cáceda R; Kinkead B; Owens MJ; Nemeroff CB J Neurosci; 2005 Dec; 25(50):11748-56. PubMed ID: 16354933 [TBL] [Abstract][Full Text] [Related]
11. Interactions between NTS2 neurotensin and opioid receptors on two nociceptive responses assessed on the hot plate test in mice. Bredeloux P; Costentin J; Dubuc I Behav Brain Res; 2006 Dec; 175(2):399-407. PubMed ID: 17074405 [TBL] [Abstract][Full Text] [Related]
12. Blockade of neurotensin receptors affects differently hypo-locomotion and catalepsy induced by haloperidol in mice. Casti P; Marchese G; Casu G; Ruiu S; Pani L Neuropharmacology; 2004 Jul; 47(1):128-35. PubMed ID: 15165840 [TBL] [Abstract][Full Text] [Related]
13. Antinociceptive, hypothermic, hypotensive, and reinforcing effects of a novel neurotensin receptor agonist, NT69L, in rhesus monkeys. Fantegrossi WE; Ko MC; Woods JH; Richelson E Pharmacol Biochem Behav; 2005 Feb; 80(2):341-9. PubMed ID: 15680187 [TBL] [Abstract][Full Text] [Related]
14. Design, synthesis, and evaluation of the antipsychotic potential of orally bioavailable neurotensin (8-13) analogues containing non-natural arginine and lysine residues. Hadden MK; Orwig KS; Kokko KP; Mazella J; Dix TA Neuropharmacology; 2005 Dec; 49(8):1149-59. PubMed ID: 16095636 [TBL] [Abstract][Full Text] [Related]
15. Antinociception induced by beta-lactotensin, a neurotensin agonist peptide derived from beta-lactoglobulin, is mediated by NT2 and D1 receptors. Yamauchi R; Sonoda S; Jinsmaa Y; Yoshikawa M Life Sci; 2003 Aug; 73(15):1917-23. PubMed ID: 12899917 [TBL] [Abstract][Full Text] [Related]
16. Repeated effects of the neurotensin receptor agonist PD149163 in three animal tests of antipsychotic activity: assessing for tolerance and cross-tolerance to clozapine. Chou S; Davis C; Jones S; Li M Pharmacol Biochem Behav; 2015 Jan; 128():78-88. PubMed ID: 25433325 [TBL] [Abstract][Full Text] [Related]
17. Neurotensin agonists: possible drugs for treatment of psychostimulant abuse. Richelson E; Boules M; Fredrickson P Life Sci; 2003 Jun; 73(6):679-90. PubMed ID: 12801589 [TBL] [Abstract][Full Text] [Related]
19. Effects of a novel neurotensin peptide analog given extracranially on CNS behaviors mediated by apomorphine and haloperidol. Cusack B; Boules M; Tyler BM; Fauq A; McCormick DJ; Richelson E Brain Res; 2000 Feb; 856(1-2):48-54. PubMed ID: 10677610 [TBL] [Abstract][Full Text] [Related]
20. Pain relief devoid of opioid side effects following central action of a silylated neurotensin analog. Tétreault P; Besserer-Offroy É; Brouillette RL; René A; Murza A; Fanelli R; Kirby K; Parent AJ; Dubuc I; Beaudet N; Côté J; Longpré JM; Martinez J; Cavelier F; Sarret P Eur J Pharmacol; 2020 Sep; 882():173174. PubMed ID: 32534076 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]